Abstract Purpose of Review This review will examine the taxonomy of PCa subclasses
across disease states, explore the relationship among specific alterations, and highlight …

Prostate cancer (PCa) is a clinically heterogeneous disease and current treatment strategies
are based largely on anatomical and pathological parameters. In the recent past, several …

Abstract Context Prostate cancer (PCa) is a clinically heterogeneous disease with marked
variability in patient outcomes. Molecular characterization has revealed striking mutational …

The remarkable variation in prostate cancer clinical behavior represents an opportunity to
identify and understand molecular features that can be used to stratify patients into clinical …

Over the past several years, analyses of data from high-throughput studies have elucidated
many fundamental insights into prostate cancer biology. These insights include the …

A subset of patients with advanced castration-resistant prostate cancer may eventually
evolve into an androgen receptor (AR)–independent phenotype, with a clinical picture …

BACKGROUND Molecular characterization of prostate cancer (PCa) has revealed distinct
subclasses based on underlying genomic alterations occurring early in the natural history of …

Prostate cancer is a clinically heterogeneous disease, with some men having indolent
disease that can safely be observed, while others have aggressive, lethal disease. Over the …

Advanced prostate cancer (PCa) treated with androgen deprivation therapy (ADT)
eventually relapses to an ADT-resistant disease referred to as castration-resistant PCa …

The term aggressive variant prostate cancer (AVPCa) refers to androgen receptor (AR)-
independent anaplastic forms of prostate cancer (PCa), clinically characterized by a rapidly …